BioAdvance News

Immunome Appoints Dr. Dennis Giesing as Chief Development Officer

By WebmasterMarch 30, 2021November 1st, 2024No Comments

Immunome Appoints Dr. Dennis Giesing as Chief Development Officer

– Pharmaceutical industry veteran brings more than three decades of experience developing innovative therapies –

Previous PostRelmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder
Next PostRide Health to Provide Non-Emergency Transportation for Complex Patient Populations Across New York State Through Partnership With IMSNY